Nanotechnology (Cancer drug delivery)

Academic Qualification

1. Ph. D. in Science: Chemistry. Awarded in 1999, University of Delhi, India.
   Title of Ph.D. Dissertation – Studies of nanometer size hydrogel particles as drug delivery systems.Bachelor of Science
2. Master of Science (M.Sc.): Chemistry, Awarded in 1994, University of Delhi, India.
   B.Sc.: Honours in Chemistry, Awarded in 1990, Utkal University, India.

Academic positions

• Scientist E, Institute of Life Sciences, Bhubaneswar – 2016 to till date
• Scientist D, Institute of Life Sciences, Bhubaneswar – 2010- 2015
• Scientist C, Institute of Life Sciences, Bhubaneswar – 2007- 2010
• Scientist B, Institute of Life Sciences, Bhubaneswar – 2005 – 2007
• Research Associate, University of Nebraska Medical Center, Omaha, NE, USA- July 2004 to June 2005
• Postdoctoral Research Associate, University of Nebraska Medical Center. Omaha, NE, USA.- September 2001 to June 2004
• Postdoctoral Research Fellow, JSPS Postdoctoral fellow, Kumamoto University School of Medicine, Kumamoto, Japan- August 1999 to August 2001
• Scientist, Dabur Research Foundation. Dabur India Ltd., India- March 1999 to August 1999
• Research Fellow, University of Nottingham, Nottingham, U. K.- January 1998 to March 1998

Awards and Recognition

1. Awarded International Fellowship for Young Biomedical Scientists in 2008 from ICMR for four months in 2008 to work at Creighton University, Omaha, Nebraska, USA.
2. Awarded travel grant from the School of Pharmacy in 1998 from University of London to attend the 3rd International symposium on Polymer Therapeutics from Laboratory to Clinical Practice, School of Pharmacy, University of London, UK.
3. Awarded Postdoctoral fellowship from the American Heart Association (AHA), United States of America (2002-2004).
4. Awarded Japanese Society for Promotion of Science (JSPS) postdoctoral fellowship from the Government of Japan (1999-2001).
5. Senior Research Fellowship (SRF, 1998-1999), University Grant Commission, Government of India.
6. All India Graduate Aptitude Test in Engineering (GATE) in 1996
7. Junior Research Fellowship (JRF, 1996-98), University Grant Commission, Government of India.

Membership of Professional Associations / Societies

• Section Editor (Cancer), Current Pharmaceutical Biotechnology
• Member, Editorial Board, Current Nanomedicine
• Member, Editorial Board, Clinical & Experimental Pharmacology

Reviewer of Scientific Journals:

Journal of Colloid and Interface Science, Biomacromolecules, Journal of Biomedical Nanotechnology, Drug Discovery Today, Export Opinion in Drug Delivery, Asain Journal of Pharmaceutics, Biomedical Materials, Future Nanomedicine, International Journal of Nanomedicine, Journal of Physics Condensed Matter, Nanotechnology, Expert Review of Molecular Diagnostics, Biomaterials, Nanomedicine: Nanotechnology, Biology and Medicine, Current Nanosciences, Pharmaceutical Research, Journal of Controlled Release, Biomacromolecules, Journal of Ameican Chemical Scociety, Small, Europian Journal of Pharmaceutics and Biopharmaceutics, Therapeutic Delivery, Tumor Biology, Chinise Medicine, future Oncology, Nanotechnology, Journal of Biomaterials Application, Cancer research, Macromolecular Biosciences, ACS Nano, Advanced Healthcare Biomaterials, Oncotarget

Nanomedicine mediated targeting of Cancer Stem-Like Cells

Chemoresistance and cancer relapse marks the significant challenges in cancer management and are attributable in part to the presence of cancer cells subpopulations termed as cancer stem cells or tumor initiating cells. Although their mode of generation and biological properties has been explored in diverse array of cancer types, our understanding of the biology of the CSCs remains superficial. Due to their extraordinary characteristics, CSCs are thought to be the basis for tumor initiation, development, metastasis and recurrence. Researchers have identified multiple potential therapeutic targets to CSCs, including the ABC superfamily, anti-apoptotic factors, detoxifying enzymes, DNA repair enzymes and distinct oncogenic cascades (such as the Wnt/β-catenin, hedgehog, EGFR and Notch pathways) which are used preferentially or uniquely by these cells. Evidences exists indicating that non-CSCs in the tumor can spontaneously and stochastically turn into CSCs de novo, undermining the efficacy of therapeutic strategy that only targets CSCs. Hence, it becomes crucial to eliminate both CSCs and non-CSCs simultaneously for effective cancer therapy. Our group is thus working on combinational approach for effective cancer treatment. We have focused our studies based on dual drug delivery systems targeting CSCs specific signaling pathway and simultaneously targeting non-CSCs to get rid of cancer relapse and metastasis in both in-vitro and in-vivo models.

Magnetic nanoparticles as a theranostic tool in cancer therapy

Development of magnetic nanoparticles (MNPs) as a theranostic agent in cancer therapy has growing importance due to their application both as a drug delivery agent for therapeutic purpose and imaging agent for diagnostic purpose. The role of MNPs as a contrast agent for the magnetic resonance imaging (MRI) has gained significant attention in cancer therapy as early diagnosis of cancer has always remained a challenge. Further, the therapeutic applications of magnetic nanoparticles account for targeted delivery of therapeutic agents and also another upcoming therapeutic mode of treatment for cancer i.e, hyperthermia. MNPs in presence of alternating magnetic field can induce heat that can kill the cancer cells and may enhance the therapeutic index of the chemotherapeutic drugs and also may help in eliminating the cancer stem cells that are the major cause of relapse of cancer. However, the majority of research in this area is still at the bench side and clinical translation is restricted by instability of the MNPs. Thus, development of aqueous dispersible magnetic nanoparticles having sufficient magnetization is necessary that can be used for different biomedical applications like drug delivery, contrast agent for MRI, hyperthermia, cell separation etc. In this regard, we have synthesized an aqueous dispersible highly stable polymer coated magnetic nanoparticle formulation (Indian Patent Application No 779/KOL/2009 of 21/5/2009 and International PCT Application No.PCT/IN09/000639 of 12/11/2009). Our lab is extensively using the above MNPs formulation for different biomedical applications for cancer management.

Total no of publications = 90

Below the publications in last five years (2012-2017)

1. Parhi P, Suklabaidya S and Sahoo SK: Enhanced anti-metastatic and antitumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo. Scientific Reports, 2017 (Press). Impact Factor- 4.25
2. Mohanty C, Sahoo SK: Curcumin and its topical formulations for wound healing applications. Drug Discov Today. 2017 (press). Impact Factor- 6.36
3. Singh D, Minz AP, Sahoo SK: Nanomedicine-mediated drug targeting of cancer stem cells. Drug Discov Today. 2017 Jun;22(6):952-959. Impact Factor- 6.36
4. Kundu P, Das M, Tripathy K and Sahoo SK: Delivery of Dual Drug Loaded Lipid Based Nanoparticles across the Blood-Brain Barrier Impart Enhanced Neuroprotection in a Rotenone Induced Mouse Model of Parkinson’s Disease. ACS Chem Neuroscience 21;7(12):1658-1670. Impact Factor- 4.34
5. Acharya S and Sahoo SK. Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavanger for inducing cytotoxicity in imatinib resistant cells. J Colloid Interface Sci. 2016; 467 (2016) 180-191. Impact Factor- 3.78.
6. Vidyasekar P, Shyamsunder P, Sahoo SK and Verma RS. Scaffold-free and scaffold-assisted 3D culture enhances differentiation of bone marrow stromal cells. In vitro Cell Dev. Biol. 2015. DOI 10.1007/s11626-015-9971-2.
7. Mohanty C, Kundu P, Sahoo SK. Brain Targeting of siRNA via Intranasal Pathway. Cur Pharm Des. 2015; 21(31):4606-13. Impact Factor- 3.05.
8. Singh A, Jain S, Senapati S, Verma RS, Sahoo SK. Magnetic Nanoparticles Labeled Mesenchymal Stem Cells: A Pragmatic Solution toward Targeted Cancer Theranostics. Adv Healthc Mater. 2015 Sep 1. doi: 10.1002/adhm.201500343. Impact Factor- 5.76.
9. Dilnawaz F, Sahoo SK.Therapeutic approaches of magnetic nanoparticles for the central nervous system. Drug Discovery Today. 2015 Oct; 20 (10):1256-64 Impact Factor- 5.62.
10. Vandana M, Sahoo SK. Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment. Eur J Pharm Biopharm. 2015 Aug;94:83-93. Impact Factor- 3.97.
11. Parhi P, Sahoo SK. Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy. J Colloid Interface Sci. 2015 Aug 1;451:198-211 Impact Factor- 3.78.
12. Das M, Duan W, Sahoo SK. Multifunctional nanoparticle-EpCAM aptamer bioconjugates: A paradigm for targeted drug delivery and imaging in cancer therapy. Nanomedicine. 2015 Feb;11(2):379-89. Impact Factor- 5.67.
13. Misra R, Das M, Sahoo BS, Sahoo SK: Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation Int J Pharm. 2014 Aug 29;475(1-2):372-384. Impact Factor- 3.99.
14. Singh A, Sahoo SK: Magnetic nanoparticles: a novel platform for cancer theranostics, Drug Discovery today, 2014, 19(4):474-81. Impact Factor- 5.62.
15. Dilnawaz F, Sahoo SK: Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model, Eur J Pharm Biopharm, 2013, 85(3):452-62. Impact Factor- 3.97.
16. Hermann PC, Trabulo SM, Sainz B Jr, Balic A, Garcia E, Hahn SA, Vandana M, Sahoo SK, Tunici P, Bakker A, Hidalgo M, Heeschen C:  Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts, PLoS One. 2013 Jun 18;8(6):e66371. Impact Factor- 3.86.
17. Mohanty C, Das M and Sahoo SK:  Emerging role of nanocarriers to increase the solubility and bioavailability of curcumin. Expert Opinion in Drug Delivery, 2012, 9(11):1347-64. Impact Factor- 5.43.
18. Mohanty C, Das M and Sahoo SK: ” Sustained wound healing activity of curcumin loaded oleic acid based polymeric bandage in a rat model: “Mol Pharm, 2012 9(10):2801-11. Impact Factor- 4.34.
19. Vandana M and Sahoo SK: Reduced Folate Carrier independent internalization of PEGylated Pemetrexed: A potential nanomedicinal approach for breast cancer therapy. Mol Pharm, 2012; 9(10):2828-43. Impact Factor- 4.34.
20. Mitra M, Mohanty C, Harilal A, Maheswari UK, Sahoo SK and Krishnakumar S: “A novel in vitro 3D retinoblastoma model for evaluating chemotherapeutic drugs” Molecular Vision 2012; 18: 1361-1378. Impact Factor- 2.11.
21. Akhtar J, Mallaredy V, Dandapat J, Maiti P,  Sahoo S.K and Singh S, PEGylation of an Osteoclast Inhibitory peptide: Suitable candidate for the treatment of Osteoporosis. Int J Pharm. 2012, 434(1-2):429-436. Impact Factor- 3.99.
22. Parhi P, Mohanty C and Sahoo S.K “Nanotechnology based combinational drug delivery: An emerging approach for cancer therapy.” Drug discovery Today, 2012, 17, 17/18, 1044-1052. Impact Factor- 5.62.
23. Das M and Sahoo S.K: Folate decorated curcumin loaded nanoparticles reverses multidrug resistance and enhances therapeutic potential of nutlin-3a in retinoblastoma, PLoS One. 2012;7(3):e32920 Impact Factor- 3.86.
24. Misra R and Sahoo S.K: Antibacterial activity of doxycycline-loaded nanoparticles, Methods Enzymol. 2012; 509:61-85. Impact Factor- 2.08.
25. Dilnawaz F, Singh A, Mewar S, Sharma U, Jagannathan NR, Sahoo SK : “The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model”. Biomaterials, 33(10):2936-51, 2012, Impact Factor-8.38.
26. Parveen S., Misra R. and Sahoo S. K.: ‘Nanoparticles: A Boon to Drug Delivery, Therapeutics, Diagnostics and Imaging’ ‘Nanomedicine: Nanotechnology, Biology, and Medicine’ Nanomedicine USA., 28(2):147-66,2012 Impact Factor-5.67.

​Nanotechnology (Cancer drug delivery)

Fahima Dilnawaz, Ph.D. DST Women Scientist Research interest: Silica/ Magnetic nanoparticle based drug delivery and imaging for cancer therapy

Chandana Mohanty, Ph.D. DST Women Scientist Research interest: Tissue engineering and nanomedicinal approach for cancer therapy

Sarbari Acharya, Ph.D. Research Associate Application of nanotechnology in lung cancer

Paromita Kundu, SRF Application of nanotechnology in Neurodegenerative disorders

Geetanjali Arya, SRF Nanomedicinal approach for the treatment of pancreatic cancer

Deepika Singh, JRF Nanomedicine mediated targeting of Cancer Stem Cells

Priya Singh, JRF

Somalisa Behera, Lab Technician

Former doctoral students

• Sarbari Acharya: Exploration of various strategies for leukemia therapy by drug loaded nanoparticles.
• Abhalaxmi Singh: An investigation on magnetic nanoparticles for stem cell based cancer theranostics.
• Priyambada Parhi: Lipid based nanoparticles: A potential targeted drug delivery system for cancer therapy.
• M. Vandana: Polymer therapeutics for effective cancer treatment using combinational approach.
• Manasi Das: Dual drug loaded immunotheranostics: A paradigm for imaging and targeted delivery for cancer therapy.
• Ranjita Misra: Nanoparticle mediated targeted delivery of doxorubicin for cancer therapy.
• Suphiya Parveen: Chitosan nanoparticles as potential drug delivery system for cancer therapy.

Former postdoctoral students

• Dr Jyotsnarani Pradhan
• Dr Sasmita Dassutar

Nanotechnology (Cancer drug delivery)